This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View
by Zacks Equity Research
AbbVie (ABBV) beats second-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.
Glaxo (GSK) Beats on Q2 Earnings, Shingrix Sales Strong
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the second quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View
by Zacks Equity Research
Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.
Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings?
by Zacks Equity Research
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
Dow 30 Stock Roundup: MSFT, JPM, IBM, JNJ, GS Earnings Impress
by Swarup Gupta
The Dow endured a volatile week, primarily due to renewed trade tensions, after gaining strongly earlier this month
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
by Kinjel Shah
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
Top Stock Reports for Johnson & Johnson, NextEra & Deere
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), NextEra (NEE) and Deere (DE).
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
by Sweta Killa
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
Company News for Jul 17, 2019
by Zacks Equity Research
Companies In The News Are: JNJ,DPZ,JBHT,CP
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
by Zacks Equity Research
AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.
Better-Than Expected Retail Sales in June
by Zacks Equity Research
Better-Than Expected Retail Sales in June
Retail Sales Up, Import Prices Down, Q2 Earnings Solid
by Mark Vickery
Retail Sales outperformed, Imports & Exports were lower, and JPM, WFC, GS and JNJ outperformed earnings expectations.
J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
Johnson & Johnson (JNJ) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 6.61% and 1.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
J&J Submits BLA for Subcutaneous Formulation of Darzalex
by Zacks Equity Research
Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.
AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.
Dow ETF Appears Strong Ahead of Q2 Earnings
by Sweta Killa
With most blue-chip companies' earnings scheduled over the coming weeks and investors' sentiment being mixed, investors should closely monitor the movement of the Dow ETF.
Why Johnson & Johnson (JNJ) Might Surprise This Earnings Season
by Zacks Equity Research
Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Company News for Jul 15, 2019
by Zacks Equity Research
Companies In The News Are: ILMN,MCRN,HI,JNJ,ACN
J&J Falls Amid Reports of Criminal Probe Into Talcum Powder
by Zacks Equity Research
The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.